MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

DaT-Scans Have Limited Utility in Predicting Treatment Response to Ventriculoperitoneal Shunts in Normal Pressure Hydrocephalus

J. Ma, M. Hamed, D. Victor, T. Kay, M. Salgado (Brooklyn, USA)

Meeting: 2023 International Congress

Abstract Number: 287

Keywords: Parkinson’s

Category: Parkinsonism, Others

Objective: To determine usefulness of DaT-SPECT imaging in the management of normal pressure hydrocephalus (NPH).

Background: Dopamine transporter single-photon emission computed tomography (DaT-SPECT) imaging is useful in detecting dopaminergic dysfunction in both idiopathic Parkinson’s disease and Parkinson-plus syndromes and are used in diagnosing conditions such as essential tremors and drug-induced parkinsonism [1,2]. Little data is available on DaT-SPECT in normal pressure hydrocephalus (NPH) and its  implications in management and prognosis.

Method: A retrospective chart review was performed on 31 patients with clinical and radiological diagnosis of NPH to determine the course and prognosis of patients with positive or negative DaT-Scans on initial presentation. A chi-square test was performed to assess differences among individuals with clinical and radiological evidence of NPH with or without response to ventriculoperitoneal shunt (VPS) placement, and presence or absence of dopaminergic dysfunction on DaT-Scan.

Results: Of the 31 patients (mean age 79 + 6.1 years) with clinical and radiological evidence of NPH, 17 had undergone DaT-Scans. Ten patients had positive DaT-Scans, 8 of which had VPS placed with 6 showing sustained treatment response (continued benefit >1 year). Five of those individuals are not on dopaminergic therapy. Seven patients with negative DaT-Scans had a VPS, 4 of them with sustained treatment response, of which 3 are not on dopaminergic therapy. Chi-square testing showed no difference in treatment response among DaT-positive and DaT-negative patients (p > 0.05).

Conclusion: Despite the use of  DaT-Scans in diagnosing Parkinson’s disease, positive DaT scans do not rule out treatment-responsive normal pressure hydrocephalus. Dopaminergic dysfunction can co-exist with NPH in a significant number of patients, and thus DaT-Scans have limited utility in ruling out NPH.

References: Kagi G, Bhatia K, Tolosa E. The role of DAT-SPECT in movement disorder. J Neurol Neurosurg Psychiatryi, 81(1):5-12.

Perlmutter J, Eidelberg D. To scan or not to scan, DaT is the question. Neurology, 78(10):688-9.

To cite this abstract in AMA style:

J. Ma, M. Hamed, D. Victor, T. Kay, M. Salgado. DaT-Scans Have Limited Utility in Predicting Treatment Response to Ventriculoperitoneal Shunts in Normal Pressure Hydrocephalus [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/dat-scans-have-limited-utility-in-predicting-treatment-response-to-ventriculoperitoneal-shunts-in-normal-pressure-hydrocephalus/. Accessed July 6, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/dat-scans-have-limited-utility-in-predicting-treatment-response-to-ventriculoperitoneal-shunts-in-normal-pressure-hydrocephalus/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley